Integra LifeSciences (NASDAQ:IART) Updates Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.400-0.450 for the period, compared to the consensus estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Stock Up 4.4 %

IART stock opened at $22.05 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.91. The firm’s 50-day simple moving average is $23.68 and its 200 day simple moving average is $21.81. The stock has a market cap of $1.70 billion, a PE ratio of -244.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IART shares. Citigroup increased their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $23.00.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.